[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-369103-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-369103-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","targeting-kras-from-metabolic-regulation-to-cancer-treatment","Targeting KRAS - from metabolic regulation to cancer treatment","","KRAS (Kirsten rat sarcoma viral oncogene homolog) drives oncogenesis, cancer progression, and metastasis, making it a central focus for therapeutic development. Numerous studies link KRAS-driven metabolic alterations to oncogenic survival and treatment resistance, motivating metabolic targeting as a cancer strategy. This review summarizes metabolic reprogramming of glucose, glutamine, and lipids governed by oncogenic KRAS, highlighting how KRAS-mutant metabolic shifts inform targeted therapy advances, including progress in KRAS inhibitor discovery and clinical trials across colorectal, pancreatic, and non-small cell lung cancer.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/targeting-kras-from-metabolic-regulation-to-cancer-treatment/369103/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/targeting-kras-from-metabolic-regulation-to-cancer-treatment/369103.png","ImageObject",300,407,{"name":42,"@type":43},"Himbo","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why is KRAS considered a challenging target in cancer therapy?","Question",{"text":63,"@type":64},"KRAS has historically been viewed as “undruggable” due to its smooth surface that limits covalent binding and its high affinity for GTP, making direct inhibition difficult.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How do oncogenic KRAS mutations affect tumor metabolism?",{"text":68,"@type":64},"KRAS mutations trigger extensive metabolic reprogramming, including increased glycolysis, glutamine addiction, and enhanced lipid metabolism, supporting rapid proliferation and adaptation to hypoxic, nutrient-poor tumor microenvironments.",{"name":70,"@type":61,"acceptedAnswer":71},"Which cancers and therapies does the review emphasize?",{"text":72,"@type":64},"The review focuses on metabolic mechanisms and KRAS inhibitor strategies in colorectal cancer, pancreatic cancer, and non-small cell lung cancer, including current clinical trials.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},369103,1790211963,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":55,"slug":125},"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},687197100911,"https://ap-avatar.wpscdn.com/avatar/a000239b6f1da00475?x-image-process=image/resize,m_fixed,w_180,h_180&k=1785132997149421697","Shi et al. Molecular Cancer (2025) 24:9 [https://doi.org/10.1186/s12943-024-02216-3](https://doi.org/10.1186/s12943-024-02216-3)  \nMolecular Cancer  \nREVIEW Open Access  \nTargeting KRAS: from metabolic regulation to cancer treatment  \nYanyan Shi 1†, Huiling Zheng2†, Tianzhen Wang3,4†, Shengpu Zhou 1, Shiqing Zhao 1, Mo Li3,4* and Baoshan Cao5*  \nAbstract  \nThe Kirsten rat sarcoma viral oncogene homolog (KRAS) protein plays a key pathogenic role in oncogenesis, cancer progression, and metastasis. Numerous studies have explored the role of metabolic alterations in KRAS-driven cancers, providing a scientific rationale for targeting metabolism in cancer treatment. The development of KRASspecific inhibitors has also garnered considerable attention, partly due to the challenge of acquired treatment resistance. Here, we review the metabolic reprogramming of glucose, glutamine, and lipids regulated by oncogenic KRAS, with an emphasis on recent insights into the relationship between changes in metabolic mechanisms driven by KRAS mutant and related advances in targeted therapy. We also focus on advances in KRAS inhibitor discovery and related treatment strategies in colorectal, pancreatic, and non-small cell lung cancer, including current clinical trials. Therefore, this review provides an overview of the current understanding of metabolic mechanisms associated with KRAS mutation and related therapeutic strategies, aiming to facilitate the understanding of current challenges in KRAS-driven cancer and to support the investigation of therapeutic strategies.  \nKeywords KRAS-driven cancers, Cancer metabolism, KRAS inhibitors, Metabolic reprogramming  \n†Yanyan Shi, Huiling Zheng and Tianzhen Wang contributed equally to this work.  \n*Correspondence: Mo Li[limo@hsc.pku.edu.cn](limo@hsc.pku.edu.cn)[ ](limo@hsc.pku.edu.cn)Baoshan Cao  \n[caobaoshan0711@aliyun.com](caobaoshan0711@aliyun.com)  \n1Research Center of Clinical Epidemiology, Peking University Third Hospital, Beijing 100191, China  \n2Department of Gastroenterology, Peking University Third Hospital, Beijing 100191, China  \n3State Key Laboratory of Female Fertility Promotion, Center for Reproductive Medicine, Department of Obstetrics and Gynecology, Peking University Third Hospital, Beijing 100191, China  \n4National Clinical Research Center for Obstetrics and Gynecology, Key Laboratory of Assisted Reproduction (Peking University), Peking University Third Hospital, Ministry of Education, Beijing 100191, China 5Department of Medical Oncology and Radiation Sickness, Peking University Third Hospital, Beijing 100191, China  \nIntroduction  \nOncogenic Kirsten Rat sarcoma viral oncogene homolog (KRAS) mutations are one of the most common and challenging drivers of human cancer, particularly in pancreatic ductal adenocarcinoma (PDAC), non-small cell lung cancer (NSCLC), and colorectal cancer (CRC) [1]. KRAS mutations play a key role in tumorigenesis and cancer progression by altering cell signaling, leading to uncontrolled proliferation and resistance to standard therapies [2]. Particularly, KRAS mutations promote tumor growth and survival through extensive metabolic reprogramming to provide nutrients and adaptation to the hypoxicand nutrient-deficient conditions of the tumor microenvironment (TME) [3]. Significant metabolic adaptations observed in these cancers include increased glycolysis, glutamine addiction, and enhanced lipid metabolism. These metabolic changes not only support rapid cell proliferation but also contribute to immune evasion by generating an immunosuppressive TME, further  \n© The Author(s) 2025. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified t","cbCaidUlOi9cnnCy","https://ap.wps.com/l/cbCaidUlOi9cnnCy","pdf",2971233,21,"English","# Introduction\n# Metabolic vulnerabilities in KRAS-driven cancers\n# KRAS targeted inhibitor discovery and strategies\n# Clinical trials in colorectal, pancreatic, and NSCLC\n# Conclusions and perspectives","[{\"question\":\"Why is KRAS considered a challenging target in cancer therapy?\",\"answer\":\"KRAS has historically been viewed as “undruggable” due to its smooth surface that limits covalent binding and its high affinity for GTP, making direct inhibition difficult.\"},{\"question\":\"How do oncogenic KRAS mutations affect tumor metabolism?\",\"answer\":\"KRAS mutations trigger extensive metabolic reprogramming, including increased glycolysis, glutamine addiction, and enhanced lipid metabolism, supporting rapid proliferation and adaptation to hypoxic, nutrient-poor tumor microenvironments.\"},{\"question\":\"Which cancers and therapies does the review emphasize?\",\"answer\":\"The review focuses on metabolic mechanisms and KRAS inhibitor strategies in colorectal cancer, pancreatic cancer, and non-small cell lung cancer, including current clinical trials.\"}]","Targeting KRAS - from metabolic regulation to cancer treatment | PDF",1790180762,53,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/15aaeac8daca73980ee1c6665da832e5.webp",983,1310,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3c68a55803591f27f4f27411910cb817.webp",982,1309,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d86ed1985b8597ab1a80a0ad1aafaac7.webp",981,1308,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6f9a639b4a4edebf5d179a69b55b69e8.webp",980,1306]